Vaxcyte (PCVX) Non Operating Investment Income (2024)

Vaxcyte (PCVX) posted quarterly Non Operating Investment Income of $1000.0 for Q3 2024, down 96.3% quarter-over-quarter from $27000.0 in Q2 2024.

Analysis

Vaxcyte (PCVX) Non Operating Investment Income (2024) Analysis & Trends

Vaxcyte (PCVX) has reported Non Operating Investment Income for 1 consecutive years, with $1000.0 the latest figure, recorded in Q3 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Vertex Pharmaceuticals	139.62 Bn	131.77 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.73 Bn	77.73 Bn	3.93 Bn	-
3	Argenx Se	63.53 Bn	58.35 Bn	1.37 Bn	-
4	Moderna	58.23 Bn	53.09 Bn	52.00 Mn	-
5	Revolution Medicines	44.05 Bn	44.05 Bn	-	-
6	BeOne Medicines	40.03 Bn	34.93 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.50 Bn	32.19 Bn	992.69 Mn	-
8	Royalty Pharma	28.52 Bn	27.68 Bn	-	-
9	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	-
10	Vaxcyte	8.83 Bn	8.83 Bn	-	-

Historic Data

Download Data